It has been suggested that TNF-a might be involved in the development of insulin resistance, inflammation and fibrosis in patients with NASH, therefore, anti-TNF medication may present a potential therapeutic target in patients with NASH [52,53,54]. This evidence concerns the gene TNF and metabolic dysfunction-associated steatohepatitis.